Status:
UNKNOWN
Intravitreal Bevacizumab for Retinal Disorders
Lead Sponsor:
Narayana Nethralaya
Conditions:
Wet AMD
Macular Oedema
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevaciz...
Detailed Description
Purpose: To study the efficacy and safety of invitreal injection of bevacizumab (avastin) in all the following conditions. * Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recu...
Eligibility Criteria
Inclusion
- Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
- Myopic CNVM, Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.
- Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
- Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
Exclusion
- Patients with poor compliance
- Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients).
- Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00403026
Start Date
August 1 2006
End Date
November 1 2006
Last Update
November 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sivakami Pai
Bangalore, India, 560010